Tag Archives: Biologics

BIO Responds to GPhA Citizen Petition on Biosimilars Naming

FDA115x76

Last September, the Generic Pharmaceutical Association (GPhA) filed a Citizen Petition with the FDA, requesting the FDA to “implement its INN naming policy equally to all biologics” and to require “all biologics approved under the Section 351(k) pathway…share the same INN [International Nonproprietary Name] as the RPP [reference protein product]” (the GPhA Petition). Today, BIO submitted our response. Contrary to the GPhA Petition, BIO believes that the legal, regulatory, and scientific principles related to biologics and biosimilarity Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Industry Growth Factor: Biologics

Graph

Last week, EvaluatePharma released their updated sales and R&D outlook for the drug industry in their report “World Preview 2013, Outlook to 2018”. Among the 37 pages of data, one central take home message was that growth will return to the sector after a small dip in 2012. Behind this predicted comeback in sales growth is the rise of biologics products that continue to gain a larger percentage of total revenue. Consider the data below taken from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Spotlight on China

Cho

The 20th annual BIO International Convention is wrapping up in Chicago. Experts and leaders from leading global biotechnology, biologics and investment companies gathered together to discuss the opportunities and challenges in the biologics industry. A large China Food and Drug Administration (CFDA) delegation led by Deputy Commissioner Bian Zhenjia participated in a half-day session dedicated to developing a world-class therapeutic biologics industry in China. There has been a shift in recent years in the usage Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , , ,

Despite Low Funding, Biotech Productivity Remains High In 2013

John Milligan

At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead Sciences, spoke in a standing room only fireside chat with Joel Sendek, Managing Director of Stifel Nicolaus, who moderated the discussion. Nicolaus noted that Gilead’s market cap has grown at an astounding 40 fold over the past 15 years, and asked Milligan to speak about the current state of the biotech industry. Milligan explained that biotech is not becoming more Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Data Exclusivity Protects Innovators and Assures Investors

medical_research_thumb

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,